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ABSTRACT
Introduction: Therapy with the SQ-standard-
ised grass sublingual immunotherapy (SLIT)-
tablet has been shown to be efficacious and
well-tolerated in a large clinical development
programme. The objective of this study was to
investigate patients’ satisfaction with treatment
by the SQ grass SLIT-tablet during routine
application.
Methods: In the setting of a non-interven-
tional, open-label, observational study, patients
with allergic rhinoconjunctivitis were started
on the SQ grass SLIT-tablet 4–5 months before
the grass pollen season and were followed until
the end of the season. Treatment satisfaction
was assessed by patients completing the Treat-
ment Satisfaction Questionnaire for Medication
(TSQM II, German version 1.4) before and after
the grass pollen season. Compliance and chan-
ges in subjective well-being were also assessed.
Results: Data of 271 patients treated with the
SQ grass SLIT-tablet by 117 allergists in Ger-
many were analysed. The TSQM score for global
satisfaction was (mean ± standard deviation)
79.40 ± 19.98 after 6–9 months of therapy, with
the highest scores for the dimensions side
effects (92.89 ± 16.49) and convenience
(88.19 ± 14.33), followed by effectiveness
(70.74 ± 25.20). Treatment effect was assessed
by the treating physician as very good or good
in 83.1% of patients. The subjective well-being
of the patients compared with the previous
years was assessed as improved by 87.8% of the
patients at the end of the study.
Conclusions: Global satisfaction measured with
the TSQM in patients treated with the SQ grass
SLIT-tablet was high, with the highest scores in
the dimensions side effects and convenience,
followed by effectiveness, and increased
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INTRODUCTION
Allergic rhinoconjunctivitis is associated with
impairments in how patients function in
day-to-day life and may significantly limit the
quality of life of the patient as well as affecting
school learning performance and work produc-
tivity [1].
Allergy immunotherapy (AIT) is currently
the only available treatment of allergic
rhinoconjunctivitis that has an effect on the
underlying chronic allergic disease and has,
therefore, the potential of being of long-term
benefit to the patient. AIT has been investigated
in several double-blind, placebo-controlled tri-
als [2–5]. While AIT was originally administered
as subcutaneous injections, alternative applica-
tions via the oral mucosal route by sublingually
applied drops and, most recently, by sublingual
tablets have become available [6]. In contrary to
AIT by subcutaneous injections (SCIT), for
which the patient has to visit the clinic at reg-
ular intervals, AIT by sublingual application
generally only requires that the patient receives
the first administration in the physician’s office
and then continues taking the medication at
home usually visiting the clinic only to arrange
follow-up prescriptions. Compliance and
adherence to treatment are therefore important
prerequisites for the effectiveness of both
administration routes, but especially for the
sublingual treatment mode as a home treatment
[7]. The SQ-standardised grass sublingual
immunotherapy (SLIT)-tablet contains a
fast-dissolving extract of Phleum pratense (ti-
mothy grass; GRAZAX; ALK, Hørsholm, Den-
mark), which is indicated for the
disease-modifying treatment of grass pollen-in-
duced rhinitis and conjunctivitis in adults and
children (5 years and older). The tolerability
and efficacy of the tablet, including long-term
efficacy and disease-modifying effect, has been
demonstrated in several randomized controlled
trials (RCTs) in Europe and USA [8–20], and
tolerability in adults and children, health-re-
lated quality of life and feasibility of intra-sea-
sonal start of treatment in real life have been
documented in several non-interventional
observational studies [21–25].
In other studies, treatment satisfaction with
medication has been found to be associated
with adherence and persistence to treatment
[26]. The Treatment Satisfaction Questionnaire
for Medication (TSQM) is a validated instru-
ment including the three most common
dimensions (i.e. medication effectiveness, side
effects of use and convenience of use) as well as
an overall satisfaction rating, representing the
individual’s judgement across all three specific
treatment attributes as most predictive indica-
tor of patient satisfaction and adherence across
different types of medication and patient pop-
ulations [27].
AIT applied as tablets over a 3-year period
can be considered to be a long-lasting treatment
of allergy. The TSQM is, therefore, a suit-
able tool to measure treatment satisfaction for
this type of treatment and to compare it with
results for treatments of other chronic diseases.
Application of the TSQM in patients treated
with AIT has currently been reported from only
one study [28]. The aim of the non-interven-
tional observational study reported here was to
measure treatment satisfaction by using the
TSQM in patients during routine treatment
with the SQ grass SLIT-tablet.
METHODS
Study Design
The study was designed as a multi-centre, open,
uncontrolled, observational study according to
non-interventional post-marketing surveillance
study guidelines included in the German drug
law for non-interventional studies analysed by
epidemiological methods after marketing
authorisation. Centres were asked to record data
on two to three patients in a consecutive order,
dependent on the patient’s willingness to
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participate in the study, in order to avoid a
selection bias. Physicians were asked to docu-
ment all patients who were potentially eligible
to be included in a patient log. The study period
was between January 2008 and March 2009.
Ethics and Data Protection
According to German drug law, the relevant
authorities must be notified of non-interven-
tional post-marketing studies. If only data on
treatment as part of the routine medical prac-
tice are recorded, these studies are not subject to
approval by an independent ethics committee.
In our study, patients were asked for their con-
sent to participate. For recording and evaluation
of data, patients were assigned a 3-digit patient
number. Direct identification of the patients
was restricted to the offices of those physicians
participating in the study.
All procedures in this study were in accor-
dance with the 1964 Helsinki declaration (and
its amendments). Since only data on treatment
as part of the routine medical practice were
recorded, the study was not subject to approval
by an independent ethics committee. Written
informed consent was not required because
only data as part of the routine medical practice
were recorded.
Patients and Treatment
Data on adult patients with a diagnosis of grass
pollen-induced rhinitis and/or conjunctivitis
with or without asthma with clinically relevant
symptoms and no contraindications to a pre-
scription of the SQ grass SLIT-tablet were eli-
gible to be documented in this study.
The study included adult patients who star-
ted their AIT with the SQ grass SLIT-tablet
(GRAZAX, Phleum pratense 75,000 SQ-T/2800
BAU, ALK-Abello´) before the grass pollen season
(GPS) 2008 (GPS1). Treatment was observed
until the end of the first GPS with the grass
SLIT-tablet (GPS2). To be included in the study,
patients had to give their consent and be can-
didates for AIT with the SQ grass SLIT-tablet
according to normal clinical practice and the
indications and contraindications described in
the Summary of Product Characteristics (SmPC)
[29]. Indications were grass pollen-induced
rhinitis and conjunctivitis in adults with clini-
cally relevant symptoms and diagnosed with a
positive skin prick test and/or specific
immunoglobulin E test to grass pollen. Con-
traindications were hypersensitivity to any of
the excipients (fish gelatin, mannitol, sodium
hydroxide), malignancy or systemic diseases
affecting the immune system (e.g. autoimmune
diseases, immune complex diseases or immune
deficiency diseases), inflammatory conditions
in the oral cavity with severe symptoms, such as
oral lichen planus with ulcerations or severe
oral mycosis, and uncontrolled or severe
asthma [in adults: FEV1 (amount of air exhaled
in first second)\70% of predicted value after
adequate pharmacologic treatment].
Determination of Treatment Satisfaction
Patients’ satisfaction during routine treatment
with the SQ grass SLIT-tablet was determined
using the TSQM II, German version 1.4 as
patient reported outcome [27]. The TSQM
comprises the dimensions effectiveness (3
items), side effects (5 items), convenience (3
items) and a global satisfaction rating (3 items).
For each dimension the calculated TSQM scores
can range from 0 (totally dissatisfied) to 100
(completely satisfied). Patients completed the
TSQM after 3 months of treatment (TSQM1)
and after 6–9 months of treatment (i.e. after the
first GPS with treatment, TSQM2).
Assessments
The time schedule and the major observations
of the study are shown in Fig. 1. At visit 1 (V1),
when the patient was enrolled in the study,
demographic data were recorded and data col-
lected on the patient’s allergy history, including
age at first appearance of symptoms, clinical
manifestation of the allergy (rhinitis/conjunc-
tivitis/asthma/atopic dermatitis), other aller-
gies, the diagnostic tests performed and
previous treatment by AIT, if applicable. The
symptoms and medication use in the previous
GPS (GPS1) were recorded retrospectively as
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nasal, ocular, bronchial and skin symptoms
assessed on a scale of 0 to 3 (no/mild/moder-
ate/severe symptoms), and the different types of
symptomatic medication (topical nasal and eye
drops/oral antihistamines/oral corticosteroids/
bronchial b-sympathomimetics/bronchial ster-
oids/other, to be specified) were recorded. The
severity of the allergic disease was graded
according to Clinical Global Impressions (CGI)
on a 7-step scale [30]. Patients were asked about
their satisfaction with the symptomatic medi-
cation in the previous GPS (GPS1, very satisfied/
satisfied/unsatisfied/very unsatisfied), and con-
comitant treatments, AIT or other medication
due to concomitant diseases were recorded. The
patient received the first treatment with the
SQ grass SLIT-tablet at V1, and adverse reac-
tions were observed during the following 30
min while the patient remained in the physi-
cian‘s office; reactions were classified as either
Fig. 1 Study diagram. Treatment was started after the
previous grass pollen season (GPS1) from January 2008
onwards with the ﬁrst intake of the SQ grass sublingual
immunotherapy (SLIT)-tablet taking place in the clinic
(V1). Patients were followed up at the 3-month visit (V2)
when they came to the physician‘s ofﬁce for the follow-up
prescription. The Treatment Satisfaction Questionnaire
for Medication (TSQM) was completed by the patient at
V2 (TSQM1) and at the ﬁnal visit (V3 or V4) after GPS
2008 (GPS2) (TSQM2), depending on when the ﬁrst
administration had been performed. CGI Clinical Global
Impressions
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‘‘tolerable’’ or ‘‘intolerable’’. Tolerable reactions
were defined as mild reactions at the applica-
tion site specified in the SmPC and, if no treat-
ment by medication was needed, not followed
further in the case report form (CRF).
The patients subsequently came to the clinic
every 3 months for follow-up prescriptions of
100 SQ grass SLIT-tablets (V2–V4). The
patients were requested to complete the TSQM
at V2 (TSQM1) and at the final visit of the study
after GPS2 (V3 or V4) after 6–9 months of
treatment with the SQ grass SLIT-tablet
(TSQM2). At visits V2, V3 and V4 the physician
asked the patient to provide additional infor-
mation regarding compliance, convenience and
satisfaction with the effect of treatment and
recorded answers to the following questions:
1. ‘‘Did the patient show up as scheduled for
the follow-up prescription? (yes/no).
2. ‘‘Did the patient take the tablets regularly in
the past interval?’’ (yes/no). If the answer
was no: ‘‘How often has the therapy been
interrupted (sometimes/frequently)?’’. The
reasons for interruptions had to be specified
(forgotten to take the tablet/side effects/
other reasons).
3. ‘‘How easy and convenient did the patient
consider the intake of the tablets?’’ (easy
and convenient/so–so/difficult or
inconvenient).
4. ‘‘How satisfied was the patient with the
effect of the SQ grass SLIT-tablet?’’ (very
satisfied/satisfied/unsatisfied/very unsatis-
fied/not assessable).
AEs were recorded as reported by the patients,
with date of start and end, severity (mild/mod-
erate/severe), causality (no relation/relation
unlikely/possible/probable/certain/unknown),
medical treatment applied, outcome (recov-
ered/recovered with sequelae/not yet recov-
ered/fatal/unknown) and seriousness. An AE
was defined as any untoward medical occur-
rence in a patient who was treated with the SQ
grass SLIT-tablet and which did not necessarily
have a causal relationship with treatment. AEs
that were at least possibly related to treatment
were classified as adverse drug reactions (ADRs).
An AE was assessed as severe when the event
considerably interfered with the patient’s daily
activities. A serious AE (SAE) was defined as any
medical occurrence or effect that was
life-threatening, required hospitalization or
prolongation of hospitalization, resulted in
persistent or significant disability or incapacity,
resulted in death, congenital abnormalities or
birth defect or any other event judged medically
important.
At the final visit (V3 or V4, depending on
whether the visit was after GPS2) global assess-
ments of the patients’ status compared to the
previous years and of the overall effect of the
SQ grass SLIT-tablet after the first GPS with
treatment (GPS2) were made by the physician,
and the overall tolerability was assessed by both
patients and physicians. Finally, the continua-
tion of treatment or discontinuation and, in
case of discontinuation, the reasons were
recorded.
Statistical Methods
For data analysis descriptive statistical methods
and exploratory tests for the comparison of
independent subgroups were used (t test, U test,
v2 test). TSQM scores of patients with evaluable
TSQM data, both after 3 months (TSQM1) and
after 6–9 months of treatment (TSQM2), were
statistically analysed by the Wilcoxon test.
Changes in TSQM scores at TSQM2 versus
TSQM1 in all patients who had completed the
TSQM questionnaire were analysed by the sign
test of Dixon and Mood. All parameters that
had been documented for the study were eval-
uated for the number of patients with respective
entries in the CRFs. Missing data were not
replaced. AEs were coded according to the cur-
rent version of the Medical Dictionary for Reg-
ulatory Activities (MedDRA). Statistical Analysis
System (SAS), version 9.3 was used as statistical
software (SAS Institute, Cary, NC).
RESULTS
Patients
Data for 271 patients treated by 117 allergists in
Germany who had their first administration of
the SQ grass SLIT-tablet in the physician’s
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office and treatment for a period of 6–9 months
on average could be evaluated. The treatment
period with the SQ grass SLIT-tablet was
between January 2008 and March 2009. Patients
were observed until the end of the first GPS with
treatment (GPS2) during their intended treat-
ment period of 3 years. The patient character-
istics are shown in Table 1, and the flow of
patients through the study is presented in Fig. 2.
TSQM Results
The TSQM scores for all patients who completed
questionnaires after 3 months of treatment with
the SQ grass SLIT-tablet at V2 (TSQM1) and
after 6–9 months of treatment at V3 or V4
(TSQM2), respectively, and for patients with
TSQM assessments at both time points (TSQM1
and TSQM2) analysed by Wilcoxon test are
shown in Fig. 3. TSQM scores for global satis-
faction and the dimensions effectiveness, side
effects and convenience were higher at TSQM2
after 6–9 months of treatment with the SQ
grass SLIT tablet than those at TSQM1 after
3 months of therapy. TSQM scores were signif-
icantly increased at TSQM2 versus TSQM1 for
effectiveness (p = 0.0219) and convenience
(p = 0.0469), but there was no significant
Table 1 Patient characteristics
Patient characteristics Values
Total number of patients 271
Age (years) 32.0 (14–71)




Patients with asthma 64 (23.6%)
Moderate to severe nasal symptoms in GPS1 250 (92.3%)
Moderate to severe eye symptoms in GPS1 209 (77.1%)
Patients ﬁrst treated with AIT 191 (70.5%)
New AIT after completed previous AIT 55 (20.3%)
Change to AIT from incomplete AIT 25 (9.2%)
CGI: ‘‘borderline to mildly ill’’ 17 (6.3%)
CGI: ‘‘moderately to markedly ill’’ 229 (84.5%)
CGI: ‘‘severely ill’’ 22 (8.1%)
Concomitant SCIT or SLIT with other allergens 21 (7.8%)
Patients with symptomatic medication in GPS1 (n = 233; 1 missing value)
Satisﬁed with effect of symptomatic medication in GPS1 94 (40.5%)
Dissatisﬁed with effect of symptomatic medication in GPS1 138 (59.5%)
Data in table are presented as the number of patients (with/without the percentage in parenthesis or as the median with the
range in parenthesis, as appropriate
GPS Grass pollen season, AIT allergy immunotherapy, CGI Clinical Global Impression, SCIT/SLIT subcutaneous/sub-
lingual Immunotherapy
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difference for side effects (p = 0.0778) and glo-
bal satisfaction (p = 0.3756). Similar results were
obtained when changes in TSQM scores were
analysed in all patients who had completed the
questionnaires at TSQM2 and TSQM1 by the
sign-test of Dixon and Mood, except that the
increase for global satisfaction was significant
(p = 0.0399). Compared to the TSQM scale
means from the validation study (effectiveness
68.6 ± 20.4, side effects 83.7 ± 19.5, conve-
nience 83.2 ± 18.7, global satisfaction
71.1 ± 22.6), [27], the TSQM scores of our
patients after 6–9 months of treatment with the
SQ grass SLIT-tablet were higher.
Compliance and Overall Satisfaction
with Treatment
Treatment satisfaction and compliance were
evaluated at each follow-up visit; 91.0–92.3% of
the patients showed up as scheduled for the
follow-up prescription. In total, 15.2% of
patients were delayed at least once in terms of
keeping a scheduled appointment. Of the 231
All patients treated with the SQ® grass SLIT-tablet n = 271 (100.0%)
No follow-up visits after first administration n =   39
Discontinuations:
• Not returned n =   30
• AEs n = 6
• Not further documented n =     2
• Other reasons n =   1
At least 1 follow-up visit n = 232 (85.6%)
Last follow-up visit before GPS2 n = 12
Discontinuations:
• AEs n = 6
• Not further documented n = 3
• Not returned n =     3
Last follow-up visit during GPS2 n = 26
Discontinuations:
• Not returned n =   16
• AEs n = 5
• Not further documented n =     4
• Other reasons n =     1
At least one post-seasonal follow-up visit n = 194 (71.6%)
Discontinuations after GPS2: n = 25
• Other reasons n =   12
• Not returned after V3 n = 7
• AEs n = 6
Continued after last post-seasonal follow-up visit n = 169 (62.4%)
Fig. 2 Flow of patients through the study. AE Adverse event, GPS grass pollen season, V visit, SLIT sublingual
Immunotherapy
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patients evaluable (1 missing value), 196
patients (84.8%) had no delays in their visits, 30
(13.0%) had one delayed visit, three (1.3%) had
two delayed visits and two (0.9%) had three
delayed visits.
At each visit 75.0–79.2% of the patients
reported to have taken the SQ grass SLIT-tablet
regularly, and 35.3% of patients reported irreg-
ularities at least once. Of 221 patients evaluable
(11 missing values), 143 (64.7%) patients
reported no deviations from taking the tablet
daily as prescribed at any of the visits, 47
(21.3%) reported deviations at one visit, 25
(11.3%) reported deviations at two visits and six
patients (2.7%) reported deviations at three
visits. The majority of patients who did not take
the SQ grass SLIT-tablet regularly only occa-
sionally interrupted the therapy (59 of 78
patients; 19 frequently).
The study was discontinued by 62 patients
(22.9%) due to compliance reasons. Patients
were considered as non-compliant if they did
not return after the last documented visit, ter-
minated treatment due to compliance reasons,
did not keep an appointment to visit the
physician’s office at least once and/or fre-
quently reported not taking the SQ grass
SLIT-tablet on a regular basis. The rate of
Fig. 3 Results of the Treatment Satisfaction Question-
naire for Medication (TSQM). TSQM scores are pre-
sented as the mean ± standard deviation after 3 months
(n = 212 patients) and after 6–9 months of treatment
(n = 174 patients) with the SQ grass SLIT-tablet and in
patients with assessments at both time points after
3 months (TSQM1) and 6–9 months of treatment
(TSQM2). Changes in TSQM scores between TSQM2
and TSQM1 assessments were statistically signiﬁcant
(asterisk) for the dimensions effectiveness (p = 0.0219,
Wilcoxon-test) and convenience (p = 0.0469); they were
not signiﬁcant for side effects (p = 0.0778) and global
satisfaction (p = 0.3756)
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compliant patients was 175 of the 271 patients
(64.6%).
At the last visit, 207 (89.6%) of the 231
evaluable patients (1 missing value) assessed the
SQ grass SLIT-tablet as ‘‘easy and convenient’’
to take as prescribed, 20 (8.7%) answered this
question as ‘‘so–so’’ and four (1.7%) reported the
therapy as ‘‘difficult and inconvenient’’. The
degree of satisfaction with the effectiveness of
the SQ grass SLIT-tablet was rated at this point
in time by 86 (37.2%) patients as ‘‘very satis-
fied’’, 107 (46.3%) as ‘‘satisfied’’, 18 (7.8%) ‘‘dis-
satisfied’’ and six (2.6%) ‘‘very dissatisfied’’; 14
(6.1%) patients were not assessable.
Effectiveness Assessment
Compared with the retrospective assessment for
GPS1, which was prior to treatment initiation
with the SQ grass SLIT-tablet, 147 of 189
(77.8%) patients evaluable were assessed to be
free of symptoms or to show improved nasal
symptoms, 133/175 (76.0%) showed improve-
ment in eye symptoms, 67/94 (71.3%) showed
improvement in bronchial symptoms and 30/44
(68.2%) showed improvement for skin symp-
toms. Symptomatic medication was no longer
used by 59 of 194 patients (31.6%; 7 missing
values) at GPS2, and 76 (40.6%) patients used
less medication at this time.
At the end of the observation period, 90.5%
of patients were assessed as improved according
to the CGI, 16.9% were assessed to be very
much improved, 50.3% as much improved and
23.3% as minimally improved. Patients’
well-being was assessed to be much better or
better by 87.8% of patients taking the SQ grass
SLIT-tablet, and the overall effectiveness was
assessed by the physician to be very good or
good in 83.1% of patients.
Tolerability Assessment
Adverse events were observed in 150 of 271
patients who were treated in total (55.4%) dur-
ing the entire observation period. Twelve
patients (4.4%) received a premedication at first
administration of the SQ grass SLIT-tablet,
predominantly antihistamines. ADRs after first
administration of the SQ grass SLIT-tablet were
reported in 134 (49.4%) patients; these were
assessed in 131 (48.3%) patients to be tolerable
and in three (1.1%) patients to be intolerable. In
102 patients with tolerable reactions, the AEs
were not further specified in the CRF (85
patients had tolerable reactions to first admin-
istration and no AEs during follow-up, 49 had
reactions to first administration and AEs during
follow-up and 16 patients had no reactions at
first administration and no AEs during fol-
low-up). The most frequent events after the first
administration recorded in the CRF (32
patients, 47 events) were MedDRA-preferred
terms paraesthesia oral (3.3% of patients), oral
pruritus (1.5%) and oedema mouth (1.5%). In
three patients with ‘‘intolerable’’ reactions,
treatment was initially continued after first
administration but discontinued after 27 days
of treatment in one patient and discontinued
due to ADRs in the later course of treatment in
two patients. In 64 (23.6%, 114 events) patients
of the 65 patients (24.0%, 121 events) with AEs
during follow-up, the AEs were assessed to be
related to treatment with the SQ grass
SLIT-tablet, and thus were ADRs. The most fre-
quent MedDRA-preferred terms were paraes-
thesia oral (5.5% of patients), oral pruritus
(2.2%) and throat irritation (2.2%); all other
events accounted for \2.0%. No SAEs were
observed. Global tolerability of the SQ grass
SLIT-tablet was assessed by 86.4% of patients
and by 86.3% of physicians to be very good
(48.5% of patients/50.0% of physicians) or good
(37.9% of patients/36.3% of physicians).
DISCUSSION
In this non-interventional, open-label, obser-
vational study that involved 271 patients trea-
ted by 117 allergists in Germany, we recorded
treatment satisfaction in patients receiving the
SQ grass SLIT-tablet using the scores of the
validated TSQM instrument as the patient
reported outcome (PRO) [26, 27]. Mean TSQM
scores were significantly increased after
6–9 months of treatment (TSQM2) versus the
first assessment after 3 months of treatment
(TSQM1) for the TSQM dimensions
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effectiveness and convenience, and they were
not significantly different for the TSQM
dimensions of side effects and global satisfac-
tion. Global satisfaction, effectiveness, side
effects and convenience were observed to be
higher after 6–9 months of treatment with the
SQ grass SLIT-tablet than the mean TSQM
scores from the TSQM validation study [27].
Physician assessment suggested that more than
75% of the patients took the tablet regularly, as
prescribed, while treatment was discontinued in
22.9% of patients due to compliance issues.
Treatment with the SQ grass SLIT-tablet con-
tinued after the last post-seasonal follow-up
visit of the study in 62.4% of the total number
of patients included in the study. Patient
well-being when taking the SQ grass SLIT-tab-
let was assessed to be much better or better by
87.8% of patients, and the effectiveness assessed
by the physician was very good or good in
83.1% of patients.
The majority of patients observed in our
study had moderate to severe rhinoconjunc-
tivitis symptoms before treatment with AIT, and
about 24% had concomitantly asthma. About
60% of the patients were quoted to be dissatis-
fied with the effect of symptomatic treatment in
the previous GPS. Data on assessments of dis-
satisfaction with symptomatic medication in
patients with allergic rhinoconjunctivitis have
been reported previously [31, 32]. In a non-in-
terventional, observational study involving
patients treated routinely with the SQ grass
SLIT-tablet and symptomatic medication as
needed, and patients treated only with symp-
tomatic medication, disease-specific and gen-
eral health-related quality of life were observed
to improve markedly during the GPS compared
with the previous GPS before the start of treat-
ment in those patients receiving the SQ grass
SLIT-tablet, while patients treated only by
symptomatic medication without AIT showed
no improvement [25].
Tolerability of treatment with the SQ grass
SLIT-tablet in adults and children [21, 23], fea-
sibility of an intra-seasonal start of treatment
[22] and tolerability in patients treated with
concomitant AIT [24] have been investigated in
other studies in the real life setting. In our
study, treatment satisfaction with the SQ grass
SLIT-tablet using the validated TSQM instru-
ment was investigated in the real-life setting.
Increases in the TSQM scores after
6–9 months versus 3 months of treatment were
predictably not very large because the tablet is
taken daily by the patient from day 1 of treat-
ment. The largest and significant increase in the
TSQM score was observed for effectiveness with
increasing duration of treatment. This was to be
expected because patients experienced symp-
toms of grass pollen exposure for the first time
after the start of treatment with the SQ grass
SLIT-tablet at the TSQM assessment after
6–9 months of treatment (TSQM2). The signifi-
cant increase in the score for satisfaction with
the convenience of the treatment may be
explained by an increasing adaption to the daily
use of the tablet.
The TSQM score for side effects did not sig-
nificantly increase, which is consistent with the
finding in RCTs with the SQ grass SLIT-tablet
that local reactions at the oral mucosa observed
in the majority of patients at the beginning of
treatment tend to decline during the first
3 months of treatment [33].
Global satisfaction did not change signifi-
cantly in patients who completed the TSQM
questionnaire at both time points (TSQM1 and
TSQM2). Analysis of the changes in TSQM
scores at TSQM2 versus TSQM1 in all patients
who had completed the TSQM questionnaire at
the two time points by the sign test (Dixon and
Mood) revealed a significant difference, sug-
gesting that treatment was discontinued by
more patients with a lower level of global sat-
isfaction than patients with high level of global
satisfaction. In the TSQM validation study,
global satisfaction with treatment has been
found to influence the decision of a patient to
continue or discontinue a treatment [27].
Analysis of the results of the TSQM valida-
tion study revealed that TSQM ratings are
influenced by the route of administration of the
drug. Oral applications had higher global and
convenience ratings and lower effectiveness
ratings than injectables [27]. In a prospective,
observational study with 30 patients allergic to
house dust mites in Spain that were treated with
a SCIT product (Dermatophagoides pteronyssinus
allergoids), TSQM mean scores of 65.2 for
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effectiveness, 76.2 for convenience, 96.4 for side
effects and 68.5 for global satisfaction were
obtained after 1 year of treatment [28].
Lower satisfaction levels were observed con-
comitantly with a higher severity of illness and
poorer appraisal of general health during the
TSQM validation study [27]. Compared with
ratings in the TSQM validation study for other
chronic diseases in patients with a mildly to
moderately serious illness and a very good/good
appraisal of general health, as well as with treat-
ment duration of between 31.0 and 125 weeks
[27], we observed in our study higher mean
TSQM scores with the sublingually applied SQ
grass SLIT-tablet after 6–9 months of treatment,
with the largest differences for global satisfac-
tion, side effects and convenience, and only a
small difference for effectiveness.
The results for the TSQM scores in our study
correspond well to the assessments of compli-
ance, convenience of taking the tablet and effect
of treatment recorded in the CRF. More than 90%
of the patients attended the scheduled visits to
the physician’s office for follow-up prescriptions
of SQ grass SLIT-tablets and rated the use of the
SQ grass SLIT-tablet to be easy and convenient,
with 65% of patients reporting that they used the
SQ grass SLIT-tablets on a regular basis. Irregu-
larities in taking the SQ grass SLIT-tablet daily as
prescribed were mainly caused by occasional
interruptions in taking the tablet. At the last
visit, 83.5% of all patients gave a global rating of
very satisfied or satisfied with treatment by the
SQ grass SLIT-tablet. Data for tolerability in our
study are consistent with data obtained in other
non-interventional studies with the SQ grass
SLIT-tablet and confirm the tolerability profile
obtained from RCTs [10, 12].
The limitations of our study are those con-
sistent with a prospective, open-label, uncon-
trolled and observational study. Patients were
recruited at sites across Germany. Physicians
were asked to include patients in a consecutive
order dependent on the consent of the patient
in order to reduce a potential selection bias.
Sources of potential bias with respect to the
effectiveness assessments in our study is the
amount of pollen grains each individual patient
was exposed to and the natural variability of the
grass pollen load in Germany in the two GPS
compared. Such variability could potentially
induce an increase in the perceived effect of
treatment by patients in the case of a lower
pollen exposure in GPS2 after 6–9 months of
treatment compared with the baseline GPS1.
CONCLUSION
In summary, our non-interventional, open-la-
bel, observational study using the TSQM
instrument as the patient reported outcome to
measure satisfaction with treatment by the SQ
grass SLIT-tablet indicates that global satisfac-
tion with the treatment, as measured by the
TSQM instrument, was similar to or higher than
average values for treatments of other chronic
diseases during routine usage. Satisfaction rat-
ings for effectiveness and convenience were
statistically significantly increased between rat-
ings after 3 months and 6–9 months of treat-
ment with the SQ grass SLIT-tablet, and they
were not significantly different for side effects
and global satisfaction.
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